发布求助
文献互助 智能选刊 最新文献

Journal of Psoriasis and Psoriatic Arthritis最新文献

筛选
英文 中文
Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis. 人口统计学背景对银屑病就医障碍影响的评估更正
Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195869
{"title":"Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis.","authors":"","doi":"10.1177/24755303231195869","DOIUrl":"10.1177/24755303231195869","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/2475530320950265.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"187"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49559680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review. 4例HIV阳性患者的生物治疗更正：病例系列和文献综述
Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195885
{"title":"Corrigendum to Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review.","authors":"","doi":"10.1177/24755303231195885","DOIUrl":"10.1177/24755303231195885","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/2475530320954279.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"192"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47083331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series. 托法替尼治疗难治性掌跖银屑病的勘误表：一系列病例
Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195857
{"title":"Corrigendum to Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series.","authors":"","doi":"10.1177/24755303231195857","DOIUrl":"10.1177/24755303231195857","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/2475530321995516.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"190"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42884289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data. 用Tildrakizumab治疗中重度斑块性银屑病患者的回顾性分析的勘误表:真实的临床数据
Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-23 DOI: 10.1177/24755303231195882
{"title":"Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data.","authors":"","doi":"10.1177/24755303231195882","DOIUrl":"10.1177/24755303231195882","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/24755303221077211.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"195"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44994620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review. 依那西普对银屑病患者剂量调整的更正:回顾性图表回顾
Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195871
{"title":"Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review.","authors":"","doi":"10.1177/24755303231195871","DOIUrl":"10.1177/24755303231195871","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/2475530320910466.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"1 1","pages":"193"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41707321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update. Brodalumab治疗难治性银屑病的勘误表：病例报告和安全性更新
Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-09-02 DOI: 10.1177/24755303231195864
{"title":"Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update.","authors":"","doi":"10.1177/24755303231195864","DOIUrl":"10.1177/24755303231195864","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/2475530320925067.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"201"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48984191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report. 固定组合0.01%丙酸盐倍他索和0.045%塔扎罗汀洗剂治疗掌跖脓疱病勘误表：一例报告
Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231196711
{"title":"Corrigendum to Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report.","authors":"","doi":"10.1177/24755303231196711","DOIUrl":"10.1177/24755303231196711","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/2475530320950290.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"186"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48092951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. Deucravacitinib:一种治疗中重度牛皮癣的新型TYK2抑制剂
Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-09-05 DOI: 10.1177/24755303231201336
Paige Kingston, Andrew Blauvelt, Bruce Strober, April W Armstrong
{"title":"Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.","authors":"Paige Kingston, Andrew Blauvelt, Bruce Strober, April W Armstrong","doi":"10.1177/24755303231201336","DOIUrl":"10.1177/24755303231201336","url":null,"abstract":"<p><strong>Background: </strong>Deucravacitinib is a first-in-class tyrosine kinase 2 (TYK2) inhibitor recently approved for the treatment of adults with moderate-to-severe plaque psoriasis.</p><p><strong>Objective: </strong>To discuss the mechanism of action, efficacy, safety, and real-world applications of deucravacitinib for the treatment of psoriasis.</p><p><strong>Methods: </strong>Literature on the mechanism of action of deucravacitinib is reviewed. The pivotal clinical studies and long-term extension studies for deucravacitinib are also examined.</p><p><strong>Results: </strong>Deucravacitinib is a novel oral TYK2 inhibitor that binds to the regulatory domain of TYK2, a Janus kinase. By inhibiting TYK2, deucravacitinib interferes with signaling of IL-23, IL-12, and type I interferons, cytokines believed to play important roles in psoriasis pathogenesis. Nearly 60% of patients achieve PASI 75 at 16 weeks of treatment; efficacy improves over 24 weeks and is maintained through 2 years of continuous treatment. In a head-to-head comparison, deucravacitinib efficacy was superior to apremilast, an older yet commonly used oral PDE4 inhibitor approved for the treatment of psoriasis. Of note, patients with moderate-to-severe plaque psoriasis with concomitant involvement of the scalp, nails, and/or palms/soles demonstrated good improvement in these high impact areas. Deucravacitinib has an acceptable safety profile and is generally well-tolerated. Small increases in reactivation of herpesvirus infections, including herpes simplex outbreaks, have been reported. Tuberculosis evaluation, but no other blood tests, is recommended prior to initiation of deucravacitinib. Monitoring of triglyceride levels should be conducted for high-risk patients according to local guidelines.</p><p><strong>Conclusion: </strong>Deucravacitinib is an effective, safe, and well-tolerated novel oral medication for adults with moderate-to-severe plaque psoriasis.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"156-165"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10768812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42868235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting Proceedings. 银屑病和银屑病关节炎临床多中心促进网络联盟（PPAACMAN）2021年会论文集
Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-09 DOI: 10.1177/24755303231195967
Carly Grant, Lourdes Perez-Chada, Rebecca H Haberman, Daniel Webster, Oliver FitzGerald, Christopher Ritchlin, Vinod Chandran, Cheryl F Rosen, Brittany Weber, Michael Garshick, Lihi Eder, Soumya M Reddy, Alexis Ogdie, Jose U Scher, Joseph F Merola
{"title":"Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting Proceedings.","authors":"Carly Grant, Lourdes Perez-Chada, Rebecca H Haberman, Daniel Webster, Oliver FitzGerald, Christopher Ritchlin, Vinod Chandran, Cheryl F Rosen, Brittany Weber, Michael Garshick, Lihi Eder, Soumya M Reddy, Alexis Ogdie, Jose U Scher, Joseph F Merola","doi":"10.1177/24755303231195967","DOIUrl":"10.1177/24755303231195967","url":null,"abstract":"<p><p>The Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) is a nonprofit organization whose mission is to optimize the clinical care of patients with psoriatic disease through multidisciplinary collaboration models. The PPACMAN 2021 Annual Meeting was held virtually on December 11, 2021. In all, 50 stakeholders participated in the meeting including dermatologists, rheumatologists, cardiologists, clinical researchers, patient advocacy representatives, and industry representatives. During the opening session of the meeting, presenters provided an update of several research projects dedicated to predicting and preventing psoriatic arthritis (PsA) such as the Psorcast, PAMPA, HIPPOCRATES, and the ELLIPSS studies. The second session centered around novel approaches to deliver multidisciplinary care in psoriatic disease. PPACMAN leadership introduced its wellness program and invited speakers to discuss new advances in cardiovascular disease, sleep disturbance, mental health problems, and dietary interventions in psoriatic disease. The final session of the meeting focused on how to improve patient engagement in their disease and care.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"179-183"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43463336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab. 英夫利昔单抗和乌斯特金单抗联合生物治疗顽固性银屑病缓解的勘误表
Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195884
{"title":"Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab.","authors":"","doi":"10.1177/24755303231195884","DOIUrl":"10.1177/24755303231195884","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/24755303211029598.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"197"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47487371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信